Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. | Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. FDA.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Alembic Pharmaceuticals received an FDA warning letter for failing to label a bioequivalence study as

U.S. FDA had inspected the facility from March 3-7, 2025

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…

Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…

The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…